CA
ABBV icon

Centerpoint Advisors’s AbbVie ABBV Stock Holding History

Centerpoint Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$321K Sell
1,478
-297
-17% -$65.9K 0.1% 67
2025
Q4 		$405K Sell
1,775
-4
-0.2% -$911 0.12% 63
2025
Q3 		$412K Buy
1,779
+84
+5% +$17.1K 0.13% 64
2025
Q2 		$315K Buy
1,695
+12
+0.7% +$2.23K 0.11% 68
2025
Q1 		$353K Buy
1,683
+3
+0.2% +$583 0.13% 62
2024
Q4 		$298K Sell
1,680
-138
-8% -$25.4K 0.1% 71
2024
Q3 		$359K Sell
1,818
-96
-5% -$17.9K 0.12% 61
2024
Q2 		$328K Sell
1,914
-149
-7% -$24.7K 0.12% 65
2024
Q1 		$376K Buy
2,063
+328
+19% +$56.5K 0.14% 56
2023
Q4 		$269K Buy
1,735
+118
+7% +$17.2K 0.11% 71
2023
Q3 		$241K Buy
1,617
+4
+0.2% +$587 0.1% 81
2023
Q2 		$217K Sell
1,613
-134
-8% -$19.6K 0.09% 83
2023
Q1 		$278K Buy
1,747
+325
+23% +$49.7K 0.12% 74
2022
Q4 		$230K Buy
1,422
+11
+0.8% +$1.69K 0.11% 79
2022
Q3 		$189K Buy
1,411
+904
+178% +$130K 0.1% 80
2022
Q2 		$78K Buy
507
+113
+29% +$17.3K 0.04% 122
2022
Q1 		$64K Buy
394
+3
+0.8% +$436 0.03% 134
2021
Q4 		$53K Buy
391
+3
+0.8% +$354 0.02% 131
2021
Q3 		$42K Buy
388
+43
+12% +$4.91K 0.02% 134
2021
Q2 		$39K Buy
+345
New +$38.9K 0.02% 139
2018
Q4 		– Sell
-675
Closed -$64K – 250
2018
Q3 		$64K Buy
675
+570
+543% +$54.1K 0.05% 87
2018
Q2 		$10K Buy
105
+39
+59% +$3.81K 0.01% 176
2018
Q1 		$6K Buy
+66
New +$7.25K 0.01% 173

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Centerpoint Advisors's ABBV Position: Q1 2026 in Review

Centerpoint Advisors reduced its AbbVie (ABBV) stake by 17% in Q1 2026, selling an estimated $65.9K and leaving 1,478 shares worth $321K. The position accounts for 0.1% of the portfolio, ranked #67.

Centerpoint Advisors first reported a position in ABBV in Q1 2018 and has held it in 23 quarters since. The position peaked at $412K in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Centerpoint Advisors held 1,478 shares of AbbVie worth $321K as of Q1 2026.
  • Centerpoint Advisors sold 297 AbbVie shares in Q1 2026, an estimated $65.9K.
  • AbbVie made up 0.1% of Centerpoint Advisors's portfolio in Q1 2026, its #67 holding.
  • Centerpoint Advisors first reported a position in AbbVie in Q1 2018 and has held it in 23 quarters since.
  • Centerpoint Advisors's AbbVie position peaked at $412K in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Centerpoint Advisors's 13F filing for Q1 2026, filed 7 May 2026.